Study of Efficacy on NT-proBNP of Recombinant Human Neuregulin-1 in Chronic Heart Failure Patients
A Phase III, Multi-center,Randomized, Double-blind, Based on Standard Therapy, Placebo-controlled Study of the Efficacy/Safety of Recombinant Human Neuregulin-1β in Patients With Chronic Systolic Heart Failure
Sponsor: Zensun Sci. & Tech. Co., Ltd.
Listed as NCT01439789, this PHASE3 trial focuses on Chronic Heart Failure and remains terminated or withdrawn. Sponsored by Zensun Sci. & Tech. Co., Ltd., it has been updated 6 times since 2011, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE3
-
Jan 2018 — Jun 2018 [monthly]
Terminated PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jan 2018 [monthly]
Terminated PHASE3
First recorded
Jun 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Zensun Sci. & Tech. Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Beijing, China, Changchun, China, Changsha, China, Chengdu, China, Chongqing, China, Dalian, China, Daqing, China, Haerbin, China, Jinan, China, Jinzhou, China and 9 more location s